KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.

Trial Details

NCT ID

NCT06026410

Phase

PHASE1

Sponsor

Kura Oncology, Inc.

Status

RECRUITING

Cancer Type

Colon Cancer Colorectal Cancer

Interventions

Darlifarnib
Cabozantinib
Adagrasib

Locations (sample)

Phoenix, Arizona, United States|33.44838,-112.07404
Tucson, Arizona, United States|32.22174,-110.92648
Los Angeles, California, United States|34.05223,-118.24368
Los Angeles, California, United States|34.05223,-118.24368
Los Angeles, California, United States|34.05223,-118.24368

Key Eligibility Criteria

At least 18 years of age.
Histologically or cytologically confirmed advanced solid tumors
Arm #1 (KO-2806 monotherapy): Patients who have progressed on, or are refractory to, standard of care (SOC) treatments with advanced solid tumors, …
Arm #2 (Combination): Patients who have received at least 1 prior systemic therapy with IO-based treatment for locally advanced or metastatic RCC w…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →